Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

37.71 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56
Open 37.71
Bid (Size) 37.00 (100)
Ask (Size) 40.00 (100)
Prev. Close 37.71
Today's Range 37.71 - 37.71
52wk Range 14.06 - 41.47
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+45.3%
+45.3%
1 Month
+3.4%
+3.4%
3 Month
+54.3%
+54.3%
6 Month
+106.3%
+106.3%
1 Year
+88.5%
+88.5%

More News

Read More
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Via The Motley Fool
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗
Via Benzinga
News headline image
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts ↗
Via Benzinga
News headline image
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co ↗
Via Benzinga
News headline image
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% ↗
Via The Motley Fool
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
What Analysts Are Saying About NewAmsterdam Pharma Co Stock ↗
Via Benzinga
News headline image
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib ↗
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Via Chartmill
News headline image
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?
Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.
What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?
NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market
What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 37.71
When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?
The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 11/20/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.